JP2023546561A - ウイルスタンパク質および宿主タンパク質の分解のためのキメラコンジュゲートならびに使用方法 - Google Patents

ウイルスタンパク質および宿主タンパク質の分解のためのキメラコンジュゲートならびに使用方法 Download PDF

Info

Publication number
JP2023546561A
JP2023546561A JP2023521735A JP2023521735A JP2023546561A JP 2023546561 A JP2023546561 A JP 2023546561A JP 2023521735 A JP2023521735 A JP 2023521735A JP 2023521735 A JP2023521735 A JP 2023521735A JP 2023546561 A JP2023546561 A JP 2023546561A
Authority
JP
Japan
Prior art keywords
peptide
chimera
seq
binding
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546561A5 (https=
Inventor
ヘンリー ディー． ハース，
ローレン ディー． ワレンスキー，
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2023546561A publication Critical patent/JP2023546561A/ja
Publication of JP2023546561A5 publication Critical patent/JP2023546561A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023521735A 2020-10-14 2021-10-14 ウイルスタンパク質および宿主タンパク質の分解のためのキメラコンジュゲートならびに使用方法 Pending JP2023546561A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091769P 2020-10-14 2020-10-14
US63/091,769 2020-10-14
PCT/US2021/054954 WO2022081827A1 (en) 2020-10-14 2021-10-14 Chimeric conjugates for degradation of viral and host proteins and methods of use

Publications (2)

Publication Number Publication Date
JP2023546561A true JP2023546561A (ja) 2023-11-06
JP2023546561A5 JP2023546561A5 (https=) 2024-10-22

Family

ID=78709532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521735A Pending JP2023546561A (ja) 2020-10-14 2021-10-14 ウイルスタンパク質および宿主タンパク質の分解のためのキメラコンジュゲートならびに使用方法

Country Status (7)

Country Link
US (1) US20230330238A1 (https=)
EP (1) EP4228699A1 (https=)
JP (1) JP2023546561A (https=)
CN (1) CN116801908A (https=)
AU (1) AU2021360898A1 (https=)
CA (1) CA3193261A1 (https=)
WO (1) WO2022081827A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024003300A1 (en) * 2022-06-30 2024-01-04 Aptadegrad, S.L. Dna aptamer conjugates recognizing and degrading coronavirus proteins
GB202214800D0 (en) 2022-10-07 2022-11-23 Tocris Cookson Ltd Compounds
GB202214796D0 (en) 2022-10-07 2022-11-23 Tocris Cookson Ltd Compounds
WO2024086132A1 (en) * 2022-10-17 2024-04-25 Ohio University Protacs targeting viral enzymes for precise treatment of covid-19
CN121889401A (zh) * 2023-10-04 2026-04-17 丹娜-法伯癌症研究院 使用靶向蛋白质降解剂对mdm2扩增癌症进行选择性抑制
WO2025245225A1 (en) * 2024-05-22 2025-11-27 Dana-Farber Cancer Institute, Inc. Stapled peptide proteolysis targeting chimeras (sp-protacs) and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118893A1 (en) * 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
WO2020041331A1 (en) * 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
PT1053019E (pt) 1998-01-07 2004-04-30 Debio Rech Pharma Sa Acrilatos de poli(etileno-glicol) heterobifuncional degradaveis e geles e conjugados derivados dos mesmos
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
BR0001870B1 (pt) 2000-05-29 2014-02-25 Peptídeo, processo de obtenção de peptídeo, formulação compreendendo peptídeo, método de prevenção de crescimento de parasitas, fungos e bactérias, método para inativar a endotoxina de bactérias gram-negativas
CN1187449C (zh) * 2003-06-05 2005-02-02 中国科学院上海药物研究所 可溶性sars病毒3cl蛋白酶的表达和纯化
ES2586387T3 (es) 2003-11-05 2016-10-14 Dana-Farber Cancer Institute, Inc. Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
WO2008106507A2 (en) 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
CA2700925C (en) 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
EP2247606B1 (en) * 2008-01-23 2019-08-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of viral infections
US8586707B2 (en) 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
CA2737922A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BRPI0920899A2 (pt) 2008-11-24 2016-04-26 Aileron Therapeutics Inc macrociclos peptidomiméticos com propriedades melhoradas
EP3549951A3 (en) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
AU2010263056B2 (en) 2009-06-18 2016-01-07 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
WO2011156524A2 (en) 2010-06-08 2011-12-15 Laura Sheard Methods and compositions for targeted protein degradation
CA2803348A1 (en) * 2010-06-25 2012-04-19 Purdue Research Foundation Pathogen detection
CA2817568A1 (en) 2010-11-12 2012-05-18 The Salk Institute For Biological Studies Intellectual Property And Tech Nology Transfer Cancer therapies and diagnostics
US9517252B2 (en) 2011-09-09 2016-12-13 Agency For Science, Technology And Research p53 activating peptides
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
WO2014052647A2 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
EP2904000A4 (en) 2012-10-01 2016-04-20 Agency Science Tech & Res PEPTIDES AND METHOD FOR THE TREATMENT OF CANCER
KR101616603B1 (ko) 2012-10-11 2016-04-28 서울대학교산학협력단 메틸 데그론 펩타이드 및 이를 이용한 단백질 수명 조절 방법
EP2912463A4 (en) 2012-10-25 2016-03-23 Agency Science Tech & Res PROCESS FOR DETERMINING THE RESISTANCE TO MOLECULES FOR THE TARGETING OF PROTEINS
WO2014065760A1 (en) 2012-10-25 2014-05-01 Agency For Science, Technology And Research Methods for determining resistance against molecules targeting proteins
US9115184B2 (en) 2013-03-01 2015-08-25 The Board Of Trustees Of The Leland Stanford Junior University Light-inducible system for regulating protein stability
AU2015320545C1 (en) * 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
US11319344B2 (en) 2015-02-13 2022-05-03 Agency For Science, Technology And Research Non-membrane disruptive P53 activating stapled peptides
US20190076504A1 (en) 2016-03-23 2019-03-14 Dana-Farber Cancer Institute, Inc. COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
US11279734B2 (en) * 2017-12-01 2022-03-22 Massachusetts Institute Of Technology Solution-phase affinity selection of inhibitors from combinatorial peptide libraries
CN110257357A (zh) * 2019-07-04 2019-09-20 中国人民解放军军事科学院军事医学研究院 MERS-CoV 3CLpro作为去泛素化酶和干扰素抑制剂的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118893A1 (en) * 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
WO2020041331A1 (en) * 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AL-HORANI, R. A. ET AL.: ""Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A", VIRUSES, vol. Vol. 12; 1092, JPN6025043091, 26 September 2020 (2020-09-26), pages 1 - 42, ISSN: 0005712012 *
KOMATSU, T. S. ET AL.: ""Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics sim", SCI. REP., vol. Vol. 10; 16986, JPN6025043094, 12 October 2020 (2020-10-12), pages 1 - 11, ISSN: 0005712011 *
LIU, Y. ET AL.: ""The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020"", EUR. J. MED. CHEM., vol. Vol. 206; 112711, JPN6025043097, 6 August 2020 (2020-08-06), pages 1 - 18, ISSN: 0005712010 *
MA, C. ET AL.: ""Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-Co", BIORXIV, [ONLINE], JPN6025043087, 16 September 2020 (2020-09-16), pages 1 - 33, ISSN: 0005712015 *
RATIA, K. ET AL.: ""A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication", PROC. NATL. ACAD. SCI. U. S. A., vol. 105, JPN6025043088, 2008, pages 16119 - 16124, ISSN: 0005712014 *
TINWORTH, C. P. ET AL.: ""PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding"", ACS CHEM. BIOL., vol. 14, JPN6025043089, 2019, pages 342 - 347, ISSN: 0005712013 *

Also Published As

Publication number Publication date
WO2022081827A1 (en) 2022-04-21
CN116801908A (zh) 2023-09-22
AU2021360898A1 (en) 2023-03-23
EP4228699A1 (en) 2023-08-23
US20230330238A1 (en) 2023-10-19
CA3193261A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
US20240140999A1 (en) Stabilized peptide-mediated targeted protein degradation
JP2023546561A (ja) ウイルスタンパク質および宿主タンパク質の分解のためのキメラコンジュゲートならびに使用方法
US12570698B2 (en) Stabilized peptides for covalent binding to target protein
EP2858661B1 (en) Stabilized antiviral fusion helices
US20140018302A1 (en) Cancer Therapies and Diagnostics
US20240075099A1 (en) COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
US11078246B2 (en) Peptides binding to Bfl-1
AU2016232833A1 (en) Selective Mcl-1 binding peptides
JP7575944B2 (ja) 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化
KR20240052851A (ko) 항바이러스성의 구조적으로 스테이플링된 SARS-CoV-2 펩티드-콜레스테롤 접합체 및 이의 용도
US20260041753A1 (en) Respiratory syncytial virus surface glycoprotein peptides, conjugates, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20251208

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20251211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260421